Fluorine-18-α–Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00464282|
Recruitment Status : Completed
First Posted : April 23, 2007
Last Update Posted : April 23, 2007
Objective: L-[3-18F]-α–methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated.
Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.
|Condition or disease|
|Carcinoma, Non-Small-Cell Lung|
|Study Type :||Observational|
|Observational Model:||Defined Population|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00464282
|Principal Investigator:||kyoichi kaira, MD||Gunma Unversity Graduate School of Medicine|